​

NeuroPace (NPCE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NPCE Stock Forecast

NeuroPace (NPCE) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $19.00, with a high of $22.00 and a low of $16.00. This represents a 34.56% increase from the last price of $14.12.

$5 $9 $13 $17 $21 $25 High: $22 Avg: $19 Low: $16 Last Closed Price: $14.12

NPCE Stock Rating

NeuroPace stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (90.00%), 1 Hold (10.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 1 9 Strong Sell Sell Hold Buy Strong Buy

NPCE Price Target Upside V Benchmarks

TypeNameUpside
StockNeuroPace34.56%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks31.16%

Price Target Trends

1M3M12M
# Anlaysts-25
Avg Price Target-$20.50$18.80
Last Closing Price$14.12$14.12$14.12
Upside/Downside-45.18%33.14%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 2616---7
Feb, 2617---8
Jan, 2617---8
Dec, 2517---8
Nov, 2526---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 27, 2026H.C. Wainwright$19.00$16.2317.07%34.56%
Dec 16, 2025UBS$22.00$15.9338.10%55.81%
Dec 09, 2025Priya SachdevaUBS$18.00$16.379.96%27.48%
Nov 05, 2025Mike KratkyLeerink Partners$19.00$9.40102.13%34.56%
Nov 05, 2025Ross OsbornCantor Fitzgerald$16.00$9.4070.21%13.31%
Aug 14, 2024Vik ChopraWells Fargo$15.00$7.28106.04%6.23%
May 23, 2024Frank TakkinenLake Street$20.00$7.99150.31%41.64%
Mar 14, 2024Larry BiegelsenWells Fargo$20.00$13.6346.74%41.64%
Nov 10, 2023Ross OsbornCantor Fitzgerald$11.00$7.8540.13%-22.10%
Jul 15, 2022Morgan Stanley$5.50$5.74-4.18%-61.05%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 27, 2026H.C. WainwrightBuyBuyhold
Jan 14, 2026UBSBuyBuyhold
Dec 09, 2025UBSBuyBuyhold
Nov 05, 2025Leerink PartnersOutperformOutperformhold
Nov 05, 2025Cantor FitzgeraldOverweightOverweighthold
Aug 14, 2024Wells FargoOverweightOverweighthold
May 29, 2024Wells FargoOverweightOverweighthold
Mar 14, 2024Wells FargoBuyOverweightupgrade
Feb 22, 2024Wells FargoBuyBuyhold
Jan 30, 2024Lake StreetUnderperformUnderperformhold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.17$-1.91$-1.27$-0.93$-0.66---
Avg Forecast$-1.88$-1.97$-1.36$-0.99$-0.89$-0.64$-0.51$0.01
High Forecast$-1.83$-1.91$-1.30$-0.96$-0.78$-0.40$-0.50$0.01
Low Forecast$-1.91$-2.02$-1.41$-1.01$-1.02$-0.89$-0.53$0.01
Surprise %15.43%-3.05%-6.62%-6.06%-25.84%---

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$45.18M$45.52M$65.42M$79.91M$99.99M---
Avg Forecast$44.92M$45.21M$64.48M$79.44M$92.39M$109.93M$155.68M$199.09M
High Forecast$45.53M$46.07M$66.03M$81.36M$93.73M$109.95M$159.44M$203.89M
Low Forecast$44.00M$44.12M$63.18M$77.84M$91.05M$109.90M$152.54M$195.07M
Surprise %0.59%0.68%1.46%0.59%8.22%---

Net Income Forecast

$-55M $-43M $-31M $-19M $-7M $5M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-36.08M$-47.08M$-32.96M$-27.14M----
Avg Forecast$-48.63M$-50.86M$-35.07M$-25.47M$-23.32M$-20.41M$-13.22M$258.52K
High Forecast$-47.33M$-49.26M$-33.65M$-24.71M$-20.25M$-10.33M$-12.84M$266.63K
Low Forecast$-49.48M$-52.12M$-36.49M$-26.24M$-26.40M$-22.98M$-13.60M$251.74K
Surprise %-25.80%-7.43%-6.03%6.55%----

NPCE Forecast FAQ

Is NeuroPace stock a buy?

NeuroPace stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that NeuroPace is a favorable investment for most analysts.

What is NeuroPace's price target?

NeuroPace's price target, set by 10 Wall Street analysts, averages $19 over the next 12 months. The price target range spans from $16 at the low end to $22 at the high end, suggesting a potential 34.56% change from the previous closing price of $14.12.

How does NeuroPace stock forecast compare to its benchmarks?

NeuroPace's stock forecast shows a 34.56% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical device stocks industry (31.16%).

What is the breakdown of analyst ratings for NeuroPace over the past three months?

  • March 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is NeuroPace’s EPS forecast?

NeuroPace's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.64, marking a -3.03% decrease from the reported $-0.66 in 2025. Estimates for the following years are $-0.51 in 2027, and $0.01 in 2028.

What is NeuroPace’s revenue forecast?

NeuroPace's average annual revenue forecast for its fiscal year ending in December 2026 is $109.93M, reflecting a 9.94% increase from the reported $99.99M in 2025. The forecast for 2027 is $155.68M, and $199.09M for 2028.

What is NeuroPace’s net income forecast?

NeuroPace's net income forecast for the fiscal year ending in December 2026 stands at $-20.408M, representing a 0% decrease from the reported $0 in 2025. Projections indicate $-13.218M in 2027, and $258.52K in 2028.